Marker Therapeutics (MRKR) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

MRKR Marker Therapeutics

Watchlist

3.0400
+0.1100+3.75%

Trading Nov 19 10:30 ET

27.13MMarket Cap-2788P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Marker Therapeutics GAAP EPS of -$0.26, Revenue of $1.93M
Seeking AlphaNov 14 17:19 ET
Marker Therapeutics | 10-Q: Q3 2024 Earnings Report
SECNov 14 17:03 ET · Announcements
Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q3 Revenue $1.9M
MT NewswiresNov 14 16:31 ET
Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswireNov 14 16:30 ET
Press Release: Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
Dow JonesNov 14 16:30 ET
Marker Therapeutics 3Q Loss/Shr 26c >MRKR
Dow JonesNov 14 16:30 ET

Comments

Green Dragon 2024

Nov 12 10:45

Thinking it’s time for data…

$Marker Therapeutics (MRKR.US)$ its been long enough for company to gather data and present. what do you say?

Jaguar8

Oct 22 14:11

Hey 👋

$Marker Therapeutics (MRKR.US)$

Green Dragon 2024

Oct 22 09:39

Good morning 😃

$Marker Therapeutics (MRKR.US)$ my little MRKR woke up! wondering do you have news coming 😊

Trytosaveabit

Aug 12 06:02

Update

$Marker Therapeutics (MRKR.US)$ Reuters· just
Marker Therapeutics Awarded $2 Million Grant From Nih in Support of Phase 1 Study Investigating MT-601 in Car-Relapsed Patients With Non-Hodgkin’s Lymphoma

Jaguar8

Aug 12 06:01

NEWS

$Marker Therapeutics (MRKR.US)$
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma
Marker Therapeutics (Nasdaq: MRKR) has been awarded a $2 million grant from the NIH Small Business Innovation Research program to support the clinical investigation of MT-601 in patients with non-Hodgkin's lymphoma (NHL) who have relapsed following anti-CD19 CAR T cell therapy. The grant will fund the nation...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

MRKR Marker Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target